Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study

Authors

Kaikai Zhao (ORCID: https://orcid.org/0000-0001-5556-2877)
Lanping Liu
Xunqiang Wang
Lulu Zhuang
Lingling Kong (ORCID: https://orcid.org/0000-0002-6266-9741)
Huijuan Zhu (ORCID: https://orcid.org/0000-0001-5172-6870)
Jun Wen (ORCID: https://orcid.org/0000-0003-2929-1270)
Wenxing Cui
Liyang Jiang (ORCID: https://orcid.org/0000-0003-2915-4495)
Zhongkai Wei (ORCID: https://orcid.org/0009-0001-1701-1043)
Xuquan Jing
Xiaoyan Yin (ORCID: https://orcid.org/0000-0001-5103-5500)
Jinming Yu (ORCID: https://orcid.org/0000-0002-8537-839X)
Minghao Yu
Xin-Jun Dong
Xiangjiao Meng

Institutions

Shandong University (CN)
Shandong Tumor Hospital (CN)
Shandong First Medical University (CN)

Publication Details

Journal: BMC Cancer
Published: 2025-03-20
DOI: https://doi.org/10.1186/s12885-025-13885-8
Citations: 2
Primary Topic: Lung Cancer Research Studies
Type: article
Field-Weighted Citation Impact: 2.09

Funders

National Natural Science Foundation of China
Natural Science Foundation of Shandong Province

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study

Kaikai Zhao, Lanping Liu, Xunqiang Wang, Lulu Zhuang et al.

Mar 20, 2025

2 citations

BMC Cancer

Lung Cancer Research Studies

2.09

article

Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study

Kaikai Zhao, Lanping Liu, Xunqiang Wang, Lulu Zhuang, Lingling Kong, Huijuan Zhu, Jun Wen, Wenxing Cui, Liyang Jiang, Zhongkai Wei, Xuquan Jing, Xiaoyan Yin, Jinming Yu, Minghao Yu, Xin-Jun Dong, Xiangjiao Meng

March 20, 2025article en

2 citations

Abstract

No abstract available for this paper.

BMC CancerVol. 25(1)

Shandong University (CN), Shandong Tumor Hospital (CN), Shandong First Medical University (CN)

National Natural Science Foundation of China, Natural Science Foundation of Shandong Province

Openalex Percentile: Top 13%

Lung Cancer Research Studies

2.09

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study — Kaikai Zhao, Lanping Liu, et al. · BMC Cancer (2025) | TGRS Research Map | TGRS